Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRX NASDAQ:NUVL NYSE:QGEN NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$6.92-5.1%$7.56$1.95▼$12.43$7.64B0.0314.09 million shs13.79 million shsNUVLNuvalent$90.95-3.3%$102.57$71.13▼$113.01$7.43B1.15773,456 shs716,007 shsQGENQiagen$36.69-2.3%$37.33$32.53▼$57.81$7.74B0.662.25 million shs1.41 million shsRXRXRecursion Pharmaceuticals$3.32-12.6%$3.30$2.77▼$7.18$2.01B1.0419.20 million shs26.80 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-5.08%-7.98%-17.42%-20.18%+136.18%NUVLNuvalent-3.27%-17.61%-12.77%-8.51%+18.39%QGENQiagen-2.19%+0.18%+6.47%-17.70%-23.81%RXRXRecursion Pharmaceuticals-12.63%-7.52%-3.21%-4.05%-32.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$6.92-5.1%$7.56$1.95▼$12.43$7.64B0.0314.09 million shs13.79 million shsNUVLNuvalent$90.95-3.3%$102.57$71.13▼$113.01$7.43B1.15773,456 shs716,007 shsQGENQiagen$36.69-2.3%$37.33$32.53▼$57.81$7.74B0.662.25 million shs1.41 million shsRXRXRecursion Pharmaceuticals$3.32-12.6%$3.30$2.77▼$7.18$2.01B1.0419.20 million shs26.80 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-5.08%-7.98%-17.42%-20.18%+136.18%NUVLNuvalent-3.27%-17.61%-12.77%-8.51%+18.39%QGENQiagen-2.19%+0.18%+6.47%-17.70%-23.81%RXRXRecursion Pharmaceuticals-12.63%-7.52%-3.21%-4.05%-32.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 2.71Moderate Buy$14.20105.20% UpsideNUVLNuvalent 2.94Moderate Buy$141.2455.29% UpsideQGENQiagen 2.42Hold$44.9822.61% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10143.98% UpsideCurrent Analyst Ratings BreakdownLatest RXRX, QGEN, IBRX, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026NUVLNuvalent Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.006/2/2026NUVLNuvalent Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/2/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/29/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/28/2026NUVLNuvalent WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$125.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026QGENQiagen Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$50.00 ➝ $36.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$113.29M63.97N/AN/A($0.51) per share-13.57NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/AQGENQiagen$2.09B3.62$3.33 per share11.03$17.89 per share2.05RXRXRecursion Pharmaceuticals$74.68M23.56N/AN/A$2.14 per share1.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)QGENQiagen$424.88M$1.9119.1613.903.7419.16%14.40%8.40%8/4/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest RXRX, QGEN, IBRX, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AQGENQiagen$0.260.71%N/A13.61%N/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest RXRX, QGEN, IBRX, and NUVL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A6.676.66NUVLNuvalentN/A16.1416.14QGENQiagen0.493.212.57RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%NUVLNuvalent97.26%QGENQiagen70.00%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio69.48%NUVLNuvalent5.02%QGENQiagen9.00%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableRXRX, QGEN, IBRX, and NUVL HeadlinesRecent News About These CompaniesInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 23,588 Shares of StockJune 6 at 7:59 AM | insidertrades.comRecursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?June 5 at 12:35 PM | zacks.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 4,386 Shares of StockJune 5 at 8:54 AM | insidertrades.comRecursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business UpdatesJune 4 at 11:18 PM | finance.yahoo.comBlake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) StockJune 4 at 7:34 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 12.5% Higher - Here's What HappenedJune 4 at 2:17 PM | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 ResultsJune 4 at 1:17 PM | finance.yahoo.comRecursion’s AI Drug Pipeline Progress Tests Investor Patience And ValuationJune 4 at 8:16 AM | finance.yahoo.comThree AI Healthcare Stocks Chart Distinct Growth TrajectoriesJune 2, 2026 | nai500.comNRecursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?June 2, 2026 | fool.comRecursion to Participate in Upcoming Investor ConferencesJune 2, 2026 | finance.yahoo.comRecursion to Participate in Upcoming Investor ConferencesJune 2, 2026 | globenewswire.comLingotto Investment Management LLP Buys 1,255,980 Shares of Recursion Pharmaceuticals, Inc. $RXRXJune 2, 2026 | marketbeat.comRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesMay 29, 2026 | finance.yahoo.comRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesMay 29, 2026 | globenewswire.comVerge, following trial failure, rebrands its AI drug discovery ambitionsMay 27, 2026 | biopharmadive.comBRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.9% Higher - Here's WhyMay 27, 2026 | marketbeat.comRecursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)May 27, 2026 | marketbeat.comRecursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?May 25, 2026 | fool.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX, QGEN, IBRX, and NUVL Company DescriptionsImmunityBio NASDAQ:IBRX$6.92 -0.37 (-5.08%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$6.90 -0.03 (-0.36%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Nuvalent NASDAQ:NUVL$90.95 -3.07 (-3.27%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$90.93 -0.02 (-0.02%) As of 06/5/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Qiagen NYSE:QGEN$36.68 -0.88 (-2.33%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$36.70 +0.01 (+0.03%) As of 06/5/2026 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Recursion Pharmaceuticals NASDAQ:RXRX$3.32 -0.48 (-12.63%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.29 -0.03 (-0.78%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
